Regeneron Pharmaceuticals (NASDAQ:REGN) said Monday that partner Hansoh Pharmaceutical Group Company Limited reported ...
SHANGHAI, Sept 23 (Reuters) - Innovent Biologics' (1801.HK), opens new tab newly launched weight-loss drug is making inroads in its home market of China, ramping up competition with its Western rivals ...
Hansoh’s olatorepatide achieved 19% weight loss at 48 weeks in a Phase 3 trial in China, handing partner Regeneron a glimmer ...
Some Chinese companies now catapulting ahead to make generic versions of Novo Nordisk's Wegovy also provided ingredients for more than a billion makeshift doses of weight-loss drugs sold online in the ...
Pfizer has claimed its first regulatory approval for a GLP-1 agonist in obesity, getting a green light in China for ecnoglutide, a once-weekly injectable drug licensed from Hangzhou-based Sciwind ...
NEW YORK (Reuters) -Some Chinese companies now racing to make generic versions of Novo Nordisk's Wegovy also supplied ingredients for more than a billion makeshift doses of weight-loss drugs sold ...
FIRST ON FOX: A Senate Republican is demanding the Food and Drug Administration (FDA) investigate whether illegal Chinese ingredients are making their way into weight loss drugs in the United States.
Add Yahoo as a preferred source to see more of our stories on Google. A sign stands outside Chinese drugmaker Innovent Biologics' office in Shanghai, China July 11, 2025. REUTERS/Andrew Silver ...
BEIJING (Reuters) -Some doctors in China want national insurance coverage for weight-loss drugs to tackle endemic obesity, medical professionals told Reuters in rare instances of public advocacy, ...
After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.78% and 10.99%, respectively, with corresponding body weight reductions of 7.72 kg and ...
SHANGHAI (Reuters) -Innovent Biologics' newly launched weight-loss drug is making inroads in its home market of China, ramping up competition with its Western rivals as it pursues a marketing strategy ...